User: Guest  Login
Title:

Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.

Document type:
Journal Article
Author(s):
Herrmann, K; Buck, AK; Schuster, T; Junger, A; Wieder, HA; Graf, N; Ringshausen, I; Rudelius, M; Wester, HJ; Schwaiger, M; Keller, U; Dechow, T
Abstract:
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma. (18)F-FDG PET has high prognostic implications at treatment completion but is limited as an early predictor. Here, we present the results of a prospective study correlating the initial uptake of the in vivo proliferation marker 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) with the clinical outcome of patients with aggressive non-Hodgkin lymphoma...     »
Journal title abbreviation:
J Nucl Med
Year:
2011
Journal volume:
52
Journal issue:
5
Pages contribution:
690-6
Language:
eng
Fulltext / DOI:
doi:10.2967/jnumed.110.084566
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/21498532
Print-ISSN:
0161-5505
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie; Institut für Medizinische Statistik und Epidemiologie; Klinik und Poliklinik für Nuklearmedizin
 BibTeX